Dean Fennell, PhD, FRCP, University Hospitals of Leicester NHS Trust, Leicester, UK, comments on the objectives and results of the ATOMIC (NCT02709512) clinical trial. This Phase II/III trial took advantage of the noticed vulnerability that non-epithelioid mesotheliomas have to arginine deprivation, and therefore studied the significance of using ADI-PEG 20, an arginine-degrading enzyme, with combination chemotherapy. The primary endpoints of PFS and OS were met. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.
